We serve Chemical Name:2,2-dimethyl-3-hexanol CAS:4209-90-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2,2-dimethyl-3-hexanol
CAS.NO:4209-90-9
Synonyms:EINECS 224-135-1;2,2-dimethylhexan-3-ol;MFCD00021929;2,2-DiMethyl-3-hexanol
Molecular Formula:C8H18O
Molecular Weight:130.22800
HS Code:2905199090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:156 °C
Density:0,82 g/cm3
Index of Refraction:1.425
PSA:20.23000
Exact Mass:130.13600
LogP:2.19350
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like EINECS 224-135-1 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2,2-DiMethyl-3-hexanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,EINECS 224-135-1 Use and application,EINECS 224-135-1 technical grade,usp/ep/jp grade.
Related News: GlaxoSmithKline��s HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection. 2,2-dimethyl-3-hexanol manufacturer Also, the study did not compare people who had COVID-19 with those who did not, to see if such symptoms were higher than in the general population. The report did exclude patients with certain serious or chronic preexisting conditions like cancer, kidney disease, HIV, liver disease and stroke, to separate their previous health status from post-COVID symptoms. 2,2-dimethyl-3-hexanol supplier A key publication in a preclinical model demonstrated rigosertib��s ability to block cellular signaling by targeting RAS effector pathways (Divakar, S.K., et al., 2016: ��A Small Molecule RAS-Mimetic Disrupts RAS Association with Effector Proteins to Block Signaling.�� Cell 165, 643). 2,2-dimethyl-3-hexanol vendor GlaxoSmithKline��s HIV drugs division ViiV Healthcare said on Saturday that the U.S. Food and Drug Administration declined to approve its long acting HIV injection. 2,2-dimethyl-3-hexanol factory Also, the study did not compare people who had COVID-19 with those who did not, to see if such symptoms were higher than in the general population. The report did exclude patients with certain serious or chronic preexisting conditions like cancer, kidney disease, HIV, liver disease and stroke, to separate their previous health status from post-COVID symptoms.
